Profile avatar
rnflex.bsky.social
Jack of all trades nurse practitioner, trail runner photographer, coonhound rescuer, lover of glucagon agonism in the liver, kidney and pancreas, fascinated by obesity medicine, retatrutide fan boy
2,833 posts 2,334 followers 376 following
Regular Contributor
Active Commenter
Posts 12 Comments 38

Fathers day feast cooking has begun!

submitted 2 hours ago • 0 comments

No insanely beautiful sunrises today but lush Midwest forests instead.

submitted 19 hours ago • 0 comments

One week til this data gets presented at ADA 2025! **Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 Weeks** At 72 weeks in this same group there was an increase in Cystatin-C GFR by 3 points vs placebo... tantalizing... #NephSky

submitted 2 days ago • 0 comments

Reasons why I don't like apple products but my job requires one: Apple says my 13 digit long password that uses words from a language only spoken by about 200K people worldwide isn't secure enough?!

submitted 3 days ago • 2 comments

Part 2 published! Last week was glucagon antagonists, this week, glucagon agonists. They're coming in 2026 and they're about to make Ozempic obsolete. Read on and find out why glucagon, once shunned by medicine is about to have its moment in the spotlight

submitted 9 days ago • 1 comment

Good morning from the Great Lakes.

submitted 4 days ago • 71 comments

This may end up as a long form post, but I have a hypothesis as to why glucagon agonist work so well for weight loss and potentially the mechanism for increased energy expenditure. Futile cycling of substrates. Specifically lipids(and to a lesser extent glucose) Here's my rationale, in a short🧵

submitted 4 days ago • 2 comments

With the American Diabetes Association Scientific conference right around the corner, expect to hear A LOT of news surrounding Amylin agonists. They may be another effective method for weight loss independently of GLP-1

submitted 6 days ago • 0 comments

Mazdutide, via its dual GLP-1/GCGR activation effects, exerts multifactorial neuroprotective-related improvements in cognitive function in male db/db mice id.elsevier.com/as/authoriza...

submitted 7 days ago • 0 comments

Apparently I'm the 1% that tries to screen a UACR on my chronic hypertension patients once a year and absolutely for a new diagnosis of HTN. Yikes. We need to do a lot better

submitted 8 days ago • 0 comments

Part 2 published! Last week was glucagon antagonists, this week, glucagon agonists. They're coming in 2026 and they're about to make Ozempic obsolete. Read on and find out why glucagon, once shunned by medicine is about to have its moment in the spotlight

submitted 9 days ago • 1 comment

New over 22 weeks dapagliflozin, as an adjunct to insulin, in youth with #T1D reduced measured eGFR (mGFR) improved glycemic control and was safe when combined with ketone testing and risk mitigation strategies @uhnresearch.ca @naturemedicine.bsky.social www.nature.com/articles/s41...

submitted 9 days ago • 0 comments